John Wiley and Sons Ltd, April 2010, Pages: 272
is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development in the future
Bizacumen Inc., Nov 2009, Pages: 305
tendencies among adolescents.
These and other market data and trends are presented in "CNS Therapeutics: World Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic
GBI Research, Dec 2009, Pages: 198
in 2008 and will be driven by the increasing ageing population and the steady increase in incidence rates of CNS complications. This market is expected to grow to $121 billion with a CAGR of 2.8% by year
Venture Planning Group, Sep 2011
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Market.
The report provides a worldwide
Medpredict, May 2010, Pages: 143
. This is the second year we’ve conducted this exercise and we provide both years’ results for comparison. The other aims of this Panel were to review progress in the development of diagnostics and imaging technology
Global Industry Analysts, Inc., April 2011, Pages: 1088
and allergy drugs, CNS drugs, and anti-infectives. Revenues in the pediatric drugs market are likely to surge in the following years, owing to new approvals of numerous existing products, as well as launch
John Wiley and Sons Ltd, Jan 2011, Pages: 252
The Year in Diabetes and Obesity will fulfill a critical need by publishing timely, thought-provoking reviews on the molecular, basic, and clinical aspects of diabetes and obesity.
Reviews
Jain PharmaBiotech, Feb 2012, Pages: 1008
as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified
GlobalData, June 2010, Pages: 55
Parkinson’s disease market to be valued at $3,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach $3,384m by 2016. This low growth is ascribed to patent expirations
Jain PharmaBiotech, Feb 2012, Pages: 772
of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress
GlobalData, Dec 2010, Pages: 39
phases of clinical development.
Scope
The scope of the report includes:
- Annualized global AIS therapeutics market revenues data from 2001 to 2009, forecast forward for 8 years to 2017
GlobalData, Dec 2010, Pages: 50
and it is forecast to remain stable with a very low growth of a CAGR of 0.2% annually for the next seven years, to reach $3.88 billion by 2017. This modest growth can be primarily attributed to population growth
GlobalData, Dec 2009, Pages: 46
of industry experts.
Scope
The scope of the report includes
- Annualized global insomnia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report
Espicom Business Intelligence Ltd, June 2010, Pages: 70
of diseases of the central nervous system (CNS). To date, the company has largely focused on drugs for psychiatry and neurology, however it has broader ambitions, namely to become one of the world’s leading
Espicom Business Intelligence Ltd, Jan 2010, Pages: 84
and the treatment of diabetes and associated complications.
This pharmaceutical company intelligence report provides a full review of the company's activities together with five-year sales forecasts for its key
GlobalData, Nov 2010, Pages: 50
.2% over the next seven years to reach $2.12 billion by 2017. The decline will be mainly due to the patent expiry of many drugs. Barriers to the insomnia market are strong in terms of both pricing (generics
